News

Zacks Investment Research on MSN16h
Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum?
Novartis AG NVS, a Swiss pharma giant, is scheduled to report first-quarter 2025 results on April 29, 2025. The Zacks ...
Novartis plans $23B expansion of manufacturing in US, including North Jersey site
Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...
Business Facilities6d
Novartis To Invest $23B In U.S. Facilities
The pharmaceutical firm will establish a research innovation hub in California, and manufacturing facilities in Florida, ...
Novartis (NVS) Unleashes $23BN Strategic Investment Masterstroke
European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.
Novartis, FDA Battle Over Generic Drug Labeling in DC Circuit
A three-judge panel wrestled Thursday with Novartis AG’s challenge against the FDA over its approval of a generic version of ...
BioPharma Dive10d
Amid tariff turmoil, Novartis commits to spending $23B on US manufacturing
Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...
Younger women diagnosed with breast cancer focus on the future
Nikki Odum was on vacation with her family when she noticed something unusual — a strange shape under her armpit near her left breast. At 36 years old, this discovery was both unexpected and alarming.
Novartis Stock Rises After Swiss Drugmaker Promises to Boost U.S. Manufacturing
A Swiss drug giant has gotten the message from President Trump’s tariff threats. Novartis said Thursday it will spend $23 ...
Hikma acquires rights to generic version of Novartis' Mekinist
Hikma Pharmaceuticals (OTCPK:HKMPF) announced on Thursday that it has acquired the FDA-approved Abbreviated New Drug ...